Where Will GW Pharmaceuticals Be in 1 Year?

Almost two years ago, the U.S. Food and Drug Administration (FDA) approved the first-ever cannabinoid-derived drug, created by GW Pharmaceuticals (NASDAQ: GWPH). The drug is called Epidolex and is used to treat patients with severe drug-resistant seizures that begin during childhood.

Since its approval, sales of Epidolex have been skyrocketing, and I think the momentum is far from over. Within the next year, Epidolex has opportunities lined up for both label expansion and international expansion. Let's take a look at these opportunities.

Image Source: Getty Images.

Continue reading

Source Fool.com